NEWS

One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104

Hackensack, NJ – March 11, 2025 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2025, ended January 31, 2025.

•Total revenue increased 42% to $17.0 million

•Gross profit of $10.4 million; gross margin of 61%

•Net income of approximately $4.5 million

•Adjusted EBITDA of $5.2 million

•Signed first data licensing deal worth up to $8.0 million

•Hired Matt Newman, Executive Vice President and General Manager, to lead and expand the development of Champions’ data licensing platform

•Total revenue increased 23% to $44.6 million

•Gross profit of $23.5 million; gross margin of 53%

•Net income of $6.5 million

•Adjusted EBITDA of $8.3 million

Ronnie Morris, CEO of Champions, commented, “Our third quarter was transformational, marked by our first major data licensing agreement - an important milestone toward monetizing our proprietary data platform." Added Morris, “Despite ongoing funding constraints in the pharma and biotech sectors, we continue to drive strong performance in our core services business."

David Miller, CFO of Champions, added, “We delivered record breaking financial results this quarter, with revenue surpassing $17.0 million and adjusted EBITDA reaching $5.2 million. While we anticipate some fluctuations in quarterly revenue, our strategic cost realignment positions us for sustained long-term profitability."

Total oncology revenue for the third quarter of fiscal 2025 was $17.0 million compared to $12.0 million for the same period last year, an increase of 42%. The increase stemmed from a 4% increase in our research services business and $4.5 million from data license revenue. Total costs and operating expenses for the third quarter of fiscal 2025 were $12.5 million compared to $14.6 million for the third quarter of fiscal 2024, a decrease of $2.1 million or 14.1%.

For the third quarter of fiscal 2025, Champions reported income from operations of $4.5 million, including $256,000 in stock-based compensation and $398,000 in depreciation and amortization expenses, compared to a loss from operations of $2.6 million, inclusive of $379,000 in stock-based compensation and $481,000 in depreciation and amortization expenses, in the third quarter of fiscal 2024. Adjusted EBITDA, which is defined as income from operations excluding stock-based compensation, depreciation and amortization expenses, was $5.2 million for the third quarter of fiscal 2025 compared to an adjusted EBITDA loss of $1.7 million in the third quarter of fiscal 2024.

Cost of oncology revenue was $6.6 million for the three-months ended January 31, 2025, a decrease of $1.2 million, or 15.7% compared to $7.8 million for the three-months ended January 31, 2024. The decrease in cost of oncology revenue was primarily from a decrease in compensation and lab supply costs due to our recent emphasis on improving efficiencies and reducing costs along with a reduction in outsourced lab services which fluctuate quarterly in the ordinary course of business. For the three-months ended January 31, 2025, total margin was 61%, with research services margin of 48% compared to 35% for the three-months ended January 31, 2024. The increase in revenue coupled with our cost reductions led to improved service margins.

Research and development expense for the three-months ended January 31, 2025 was $1.7 million, a decrease of $467,000 or 21.4%, compared to $2.2 million for the three-months ended January 31, 2024. The decrease was primarily due to reduced investment in our wholly owned subsidiary, Corellia, focused on target discovery. Sales and marketing expense for the three-months ended January 31, 2025 was $1.8 million, essentially flat with a nominal increase of $9,000, or 0.5%, compared to $1.8 million for the three-months ended January 31, 2024. General and administrative expense for the three-months ended January 31, 2025 was $2.4 million, a decrease of $366,000, or 13.2%, compared to $2.8 million for the three-months ended January 31, 2024. The decrease was primarily from a decline in compensation expense and non-cash items of stock-based compensation and depreciation and amortization.

Net cash provided by operating activities was approximately $918,000 for the three-months ended January 31, 2025 and was primarily due to net income for the quarter offset by an increase in accounts receivable. Net cash used in investing activities for the three-months ended January 31, 2025 was approximately $470,000 for lab and computer equipment. Net cash provided by financing activities for the three-months ended January 31, 2025 was nil resulting from proceeds from options exercise of approximately $38,000 offset by financing lease payments of approximately $38,000.

The Company ended the quarter with cash on hand of approximately $3.2 million. The Company has no debt.

Total oncology revenue for the nine-months ended January 31, 2025 was $44.6 million compared to $36.2 million for the same period last year, an increase of 23.3%. Total costs and operating expenses for the nine-months ended January 31, 2025 were $38.0 million compared to $43.2 million for the same period of fiscal 2024, a decrease of $5.2 million or 12.0%.

For the nine-months ended January 31, 2025, Champions reported income from operations of $6.6 million, including $523,000 in stock-based compensation and $1.2 million in depreciation and amortization expenses, compared to a loss from operations of $7.1 million, inclusive of $855,000 in stock-based compensation and $1.4 million in depreciation and amortization expenses, over the same period of fiscal 2024. Excluding stock-based compensation, depreciation and amortization expenses, Champions reported adjusted EBITDA of $8.3 million for the nine-months ended January 31, 2025 compared to an adjusted EBITDA loss of $4.8 million over the same period last year.

Cost of oncology revenue was $21.1 million for the nine-months ended January 31, 2025, a decrease of $1.0 million, or 4.7% compared to $22.2 million for the nine-months ended January 31, 2024. The decrease in cost of oncology revenue was primarily from a decrease in compensation and lab supplies expenses offset by an increase in mice costs. For the nine-months ended January 31, 2025, total margin was 53%, with research services margin of 48% compared to 39% for the nine-months ended January 31, 2024. The improved margin resulted primarily from a combination of an increase in revenue while reducing costs due to operational efficiencies implemented and other cost reduction initiatives.

Research and development expense for the nine-months ended January 31, 2025 was $4.9 million, a decrease of $2.6 million or 35.1%, compared to $7.5 million for the nine-months ended January 31, 2024. The decrease was primarily due to reduced investment in research and development in non-essential services, including Corellia, our wholly-owned subsidiary. Sales and marketing expense for the nine-months ended January 31, 2025 was $5.2 million, a slight decrease of $52,000, or 1.0%, compared to $5.3 million for the nine-months ended January 31, 2024. General and administrative expense for the nine-months ended January 31, 2025 was $6.8 million, a decrease of $1.5 million, or 18.0%, compared to $8.3 million for the nine-months ended January 31, 2024. The decrease was primarily from a reduction in compensation, recruitment, and stock-based compensation expenses.

Conference Call Information:

The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its third quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 403045, or provide the verbal reference "Champions Oncology".

Full details of the Company’s financial results will be available by or before March 17, 2025 in the Company’s Form 10-Q at www.championsoncology.com.

This press release contains “Non-GAAP financial measures,” which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”).

A further explanation and reconciliation of these Non-GAAP financial measures is included below and in the financial tables in this release.

The Company believes that the Non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company’s management uses Non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results and for internal planning and forecasting purposes. Adjusted EBITDA and Adjusted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company’s Adjusted EBITDA and Adjusted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate Non-GAAP financial results differently, particularly related to nonrecurring, unusual items.

Adjusted EBITDA

Adjusted EBITDA represents net income (loss), or net income (loss) from operations, excluding the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.

Adjusted Net Income (Loss) and Adjusted Earnings Per Share (EPS)

Adjusted net income (loss) (if denoted) and adjusted EPS exclude the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

 

 

  

 

 

 

 

 

 

			Nine Months Ended January 31,
			2025						2024
Cash flows from operating activities:
Net income (loss)			$	6,536					$	(7,167)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operations:
Stock-based compensation expense			523						855
Operating lease right-of use assets			881						782
Depreciation and amortization expense			1,246						1,410
Loss on disposal of equipment			—						81
Allowance for doubtful accounts and estimated credit losses			(320)						314
Changes in operating assets and liabilities			(7,920)						(596)
Net cash provided by (used in) operating activities			946						(4,321)
Cash flows from investing activities:
Purchases of property and equipment			(564)						(839)
Net cash used in investing activities:			(564)						(839)
Cash flows from financing activities:
Repurchases of common stock			—						(634)
Proceeds from the exercise of stock options			314						252
Finance lease payments			(112)						(108)
Net cash provided by (used in) financing activities:			202						(490)
Net increase (decrease) in cash			584						(5,650)
Cash at beginning of period			2,618						10,118
Cash at the end of period			$	3,202					$	4,468